Equities analysts expect that Bristol-Myers Squibb Company (NYSE:BMY) will post $5.18 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Bristol-Myers Squibb’s earnings, with estimates ranging from $5.10 billion to $5.27 billion. Bristol-Myers Squibb reported sales of $4.92 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 5.3%. The company is expected to issue its next earnings report before the market opens on Thursday, October 26th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full year sales of $5.18 billion for the current year, with estimates ranging from $20.42 billion to $20.77 billion. For the next year, analysts forecast that the firm will report sales of $21.14 billion per share, with estimates ranging from $20.82 billion to $21.52 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.69 earnings per share.

Several analysts have weighed in on the stock. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Wednesday, August 16th. BMO Capital Markets reissued an “underperform” rating and issued a $47.00 price target (down from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. Leerink Swann lowered their price target on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research note on Friday, July 28th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, Cowen and Company reissued a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $64.53.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/5-18-billion-in-sales-expected-for-bristol-myers-squibb-company-bmy-this-quarter.html.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after purchasing an additional 333,685 shares during the period. BlackRock Inc. grew its holdings in Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after purchasing an additional 2,367,864 shares during the period. State Street Corp grew its holdings in Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the period. Dodge & Cox grew its holdings in Bristol-Myers Squibb by 1.6% in the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after purchasing an additional 459,271 shares during the period. Finally, Northern Trust Corp grew its holdings in Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after purchasing an additional 910,496 shares during the period. Institutional investors own 68.90% of the company’s stock.

Bristol-Myers Squibb (BMY) traded down 0.09% during mid-day trading on Tuesday, reaching $63.69. The company had a trading volume of 3,149,749 shares. The firm has a 50-day moving average price of $63.48 and a 200 day moving average price of $57.42. The firm has a market capitalization of $104.45 billion, a price-to-earnings ratio of 23.26 and a beta of 1.19. Bristol-Myers Squibb has a 12-month low of $46.01 and a 12-month high of $66.10.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 2.45%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.